IBRX vs PG · rev $113.3M vs P/E 25, rev $84.28B
Immunitybio Inc (IBRX) versus Procter & Gamble Company (PG) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Procter & Gamble Company (PG) is a household & personal products company listed on US. It is led by Jon Moeller.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Latest reported PG revenue for 2025-06-30 was $84.28B. Net income was $15.97B. PG currently screens at market cap $373.53B and trailing P/E 25.3.
IBRX currently screens at market cap $7.88B. PG currently screens at market cap $373.53B and trailing P/E 25.3.
Not investment advice. Open the IBRX and PG stock pages for the full models.
Not investment advice.